Phase I/II Assessment of Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT
Status:
Not yet recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This a Phase I/II randomized trial for patients with relapsed refractory Multiple Myeloma who
have relapsed after treatment with prior therapies. The protocol is designed to evaluate two
agents, Anti-LAG-3 and Anti-TIGIT, in order to understand their immunologic effects and
safety both as single agents and in combination with pomalidomide and dexamethasone. In these
arms, patients will be treated with either Anti-LAG-3 or Anti-TIGIT respectively for one
cycle as single agent followed by the addition of pomalidomide and dexamethasone in
combination for subsequent cycles.
A third arm allows patients to be treated with the FDA approved combination of elotuzumab
plus pomalidomide and dexamethsone as a control. This arm will thus allow a concurrent
standard of care comparator for the experimental arms.